Focus: Iambic Therapeutics is an AI-driven drug discovery biotech founded in 2023, headquartered in San Diego, focusing on oncology, neurology, and gastroenterology indications. The company leverages artificial intelligence to accelerate target identification and drug candidate generation across multiple therapeutic areas.
Profile data last refreshed 4h ago · AI intelligence enriched 1w ago
Stable — net +2 jobs in 30d
8 added, 6 removed. Backfill posture.
High-upside early-stage bet for technologists and scientists willing to accept pre-revenue risk in exchange for ownership optionality and strategic pharma validation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Iambic Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Iambic Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
How Bayer Uses AI to Advance Drug Discovery With Iambic - Healthcare Digital
How Bayer Uses AI to Advance Drug Discovery With Iambic Healthcare Digital
Bayer and Iambic Partner to Advance AI-Driven Drug Discovery - CHEManager
Bayer and Iambic Partner to Advance AI-Driven Drug Discovery CHEManager
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities - Ophthalmology Times Europe
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities Ophthalmology Times Europe
Bayer taps Iambic’s AI to find harder-to-drug targets - Stock Titan
Bayer taps Iambic’s AI to find harder-to-drug targets Stock Titan
Bayer taps Iambic’s AI platform in new drug discovery collaboration - The Pharma Letter
Bayer taps Iambic’s AI platform in new drug discovery collaboration The Pharma Letter
Bayer and Iambic collaborate to advance drug discovery with AI - Bayer
Bayer and Iambic collaborate to advance drug discovery with AI Bayer
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 7 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo